Earnings Outlook for Onconova Therapeutics

Onconova Therapeutics ONTX announces its next round of earnings this Monday, May 17. Here is Benzinga's everything-that-matters guide for this Monday's Q1 earnings announcement.

What Are Earnings, Net Income, And Earnings Per Share?

Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.

Earnings And Revenue

Analysts are predicting Onconova Therapeutics will report a loss of $0.03 per share on revenue of $60.00 thousand. Onconova Therapeutics EPS in the same period a year ago totaled $0.03. Revenue was $52.00 thousand.

Why Analyst Estimates And Earnings Surprises Are Important

Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.

The analyst consensus estimate would represent a 0% decrease in the company's earnings. Revenue would be up 15.38% on a year-over-year basis. Onconova Therapeutics's reported EPS has stacked up against analyst estimates in the past like this:

Stock Performance

Over the last 52-week period, shares are up 40.26%. Given that these returns are generally positive, long-term shareholders can be content going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. Onconova Therapeutics is scheduled to hold the call at 16:30:00 ET and can be accessed here.